Myriad Genetics earnings date
Myriad Genetics (MYD) Q3 2026 Earnings Report
DE:MYD Q3 2026 EPS Results
- Actual EPS
- -EUR 0.10
- Consensus EPS
- -EUR 0.18
- Beat/Miss
- Beat by +EUR 0.08
- One Year Ago EPS
- EUR 0.00
DE:MYD Q3 2026 Revenue Results
- Actual Revenue
- EUR 184.78M
- Expected Revenue
- EUR 174.41M
- Beat/Miss
- Beat by +EUR 10.36M
- YoY Revenue Growth
- -1.46%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/04/2026
- Time
- After Close
- Conference Call
- Wednesday, November 4, 2026
Myriad Genetics's next earnings date is estimated for March 2, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was broadly constructive. Management reported sequential improvement in revenue per test, gross margin, adjusted EBITDA, Cancer Care and Mental Health volumes, and raised full-year revenue guidance. The Prenatal Health divestiture, expected to strengthen focus, liquidity, growth, and margins, was presented as a major strategic positive. However, the company continues to face Prenatal Health volume and revenue declines, HCT reimbursement pressure, year-over-year gross-margin contraction, adjusted losses, and unresolved reimbursement and profitability work. The positive developments and strategic actions significantly outweighed the stated challenges.
For full-year 2026, total revenue guidance is a range of $780 million to $790 million, with the midpoint raised to $785 million from $780 million, reflecting conservative assumptions related to Prenatal Health testing volume; Q4 guidance assumes prenatal volume softness tied to the deal announcement of about half or $5 million worth of prenatal revenue. Longer term, the company expects modest pressure on Hereditary Cancer Testing average revenue per test, framed as 1% to 5%, maybe more like 3% to 5% in some years, with some years it may be in excess of 5%, some years it might be down 1% or may even be flat. Precise MRD reimbursement for breast cancer is expected to begin in the first half of 2027, with reimbursement for colorectal and renal cancer later in 2027; post-divestiture, revenue growth is expected to improve over 100 basis points, gross margins are expected to increase or improve by greater than 500 basis points, and the company expects meaningful progress in 2027 as it relates to bottom line profitability.
- Third-Quarter Revenue and Revenue-per-Test ImprovementThird-quarter revenue was $202.7 million, up 6% sequentially and down 1% year-over-year. Average revenue per test increased 7% sequentially and 1% year-over-year, improving from a 9% year-over-year decline in Q2. Management attributed the improvement to product mix, a more normalized year-over-year comparison, and early progress from revenue-cycle initiatives.
- Cancer Care Continuum Volume GrowthCancer Care Continuum revenue was $124 million, up 1% year-over-year. Test volume increased 4% to 98,000 tests, although average revenue per test declined 3%. Hereditary Cancer Testing volume grew 6% year-over-year, with growth in both unaffected and affected populations.
- Record Unaffected Hereditary Cancer Testing VolumeUnaffected Hereditary Cancer Testing volume in Q3 reached its highest recorded level in the last three years. Management cited clinically relevant content, a strong market position, and improving commercial execution as contributors to continued HCT volume growth.
- Guideline Expansion Supporting Hereditary Cancer TestingManagement highlighted NCCN guideline updates, including multi-gene panel testing for all patients with endometrial cancer and for colorectal and gastric cancers regardless of age and family history. Management said guideline expansion is expected to continue supporting growth in future years.
- Early Progress on Reimbursement and Revenue-Cycle InitiativesManagement reported early progress from payer engagement, revenue-cycle management optimization, AI-enabled workflow acceleration, MyRisk reimbursement initiatives, policy engagement, LBM collaboration, and reimbursement optimization. This progress contributed to the sequential improvement in HCT average revenue per test, although management said more work remains.
- Improved Gross Margin and Adjusted EBITDAGross margin was 67.9%, improving 130 basis points sequentially. Adjusted EBITDA improved sequentially to a loss of $5 million, or approximately negative $5.3 million in management's prepared remarks, driven by stronger revenue performance and disciplined operating-expense management.
- GeneSight Revenue and Provider-Basis GrowthGeneSight generated $40 million of third-quarter revenue, up 2% year-over-year on 3% year-over-year volume growth. The ordering-provider base exceeded 40,000 clinicians, and management said the volume growth reflected positive underlying demand and sales performance.
- Positive Precise MRD Interim DataIn an interim analysis of colorectal cancer patients in the MONSTAR-3 study, 91% of patients who recurred were MRD-positive by Precise MRD one month after surgery. The remaining 9% who recurred were identified as positive through serial testing. Approximately half of post-surgery ctDNA-positive results were detected at an ultrasensitive level, and 35% of patients who had recurred were first detected at an ultrasensitive level.
- Precise MRD Commercial and Reimbursement ProgressPrecise MRD is being used at early-access customer sites, with management monitoring test utilization, customer experience, and internal operational efficiency. Breast cancer reimbursement is expected to begin in the first half of 2027, with submission to MolDX planned for this summer; reimbursement for colorectal and renal cancer is expected later in 2027.
- Prenatal Health Divestiture AgreementMyriad signed a definitive agreement to sell its Prenatal Health business to Labcorp for $210 million plus inventory in an all-cash transaction, valuing the business at 1.3x trailing 12-month revenue. Management said investor feedback had been unanimously positive and expects the transaction to preserve uninterrupted patient access while approximately 500 employees move to Labcorp.
- Greater Strategic Focus on Cancer CareManagement said the Prenatal Health divestiture will allow Myriad to prioritize resources and investment on the Cancer Care Continuum, where it believes the company has its strongest long-term value-creation opportunities. The transaction is expected to provide a more focused organization and greater emphasis on serving patients and clinicians in the Cancer Care Continuum.
- Expected Post-Divestiture Financial Profile ImprovementManagement expects revenue growth to improve by over 100 basis points after the divestiture and gross margins to improve by greater than 500 basis points. Management also expects meaningful progress in bottom-line profitability in 2027, while stating that detailed profitability guidance will be provided closer to 2027.
- Stronger Liquidity and Capital FlexibilityMyriad ended the quarter with approximately $182 million in available capital. The $210 million plus inventory divestiture proceeds are expected to strengthen the balance sheet and increase financial flexibility. Potential uses include some debt repayment, internal and external growth investments, and typical operating needs.
- Ascend Operating-Model InitiativeMyriad is advancing the multiyear Ascend initiative with a leading consulting firm to modernize processes and organizational design through new tools and technologies. Management said the initiative is intended to improve customer service, market competitiveness, productivity, efficiency, and the cost structure, with more detail expected as the company moves into 2027.
- Raised 2026 Revenue GuidanceFull-year 2026 revenue guidance was raised to $780 million to $790 million, with the midpoint increasing from $780 million to $785 million. The increase primarily reflects third-quarter average-revenue-per-test improvement, partially offset by potential Prenatal Health volume softness associated with the divestiture announcement.
- Execution of Key Product and Commercial MilestonesManagement said the majority of key milestones related to Hereditary Cancer Testing, prostate cancer, and Precise MRD had been completed as the year approached its final months. These milestones included product launches, publications, and submissions intended to support future Cancer Care Continuum growth.
DE:MYD Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 02, 2027 | 2026 (Q4) | -0.21- | 0.04 | ― | ― |
| Nov 04, 2026 | 2026 (Q3) | -0.18-0.10 | 0 | ― | |
| Jul 30, 2026 | 2026 (Q2) | -0.05-0.23 | 0.05 | -600.00% (-0.27) | |
| May 05, 2026 | 2026 (Q1) | -0.06-0.08 | -0.03 | -200.00% (-0.05) | |
| Feb 23, 2026 | 2025 (Q4) | -0.010.04 | 0.03 | 33.33% (+0.01) | |
| Nov 03, 2025 | 2025 (Q3) | -0.010.00 | 0.05 | -100.00% (-0.05) | |
| Aug 05, 2025 | 2025 (Q2) | -0.010.05 | 0.05 | 0.00% (+0.00) | |
| May 06, 2025 | 2025 (Q1) | -0.05-0.03 | -0.01 | -200.00% (-0.02) | |
| Feb 24, 2025 | 2024 (Q4) | 0.030.03 | 0.04 | -25.00% (-0.01) | |
| Nov 07, 2024 | 2024 (Q3) | 0.020.05 | -0.03 | 300.00% (+0.08) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


